Immix Biopharma Inc (IMMX NASDAQ) stock market data APIs
$9.6927
0.42(4.3%)
as of October 6, 2026
Try our APIs with
free plan!
Immix Biopharma Inc Financial Data Overview
Price chart is built with
Anychart
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Prev. Close
9.6927
Open
10.1151
High
10.1537
Low
9.591
52 wk Range
2.31-15.1
Market Cap
799 M
Shares Outstanding
82 903 K
EPS
-0.18
Beta
0.241
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Immix Biopharma Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Immix Biopharma Inc data using free add-ons & libraries
Get Immix Biopharma Inc Fundamental Data
Immix Biopharma Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -41 484 312
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-07
- EPS/Forecast: -0.17
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Immix Biopharma Inc News
New
Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock
Immix Biopharma, Inc. – Financing includes leading U.S. biotechnology institutional investors and mutual funds – LOS ANGELES, CA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("Immix...
Immix Biopharma Investigated by the Portnoy Law Firm
LOS ANGELES, July 21, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Immix Biopharma, (“Immix" or the "Company") (NASDAQ: IMMX) investors that the firm has initiated an investigation into p...
Straight Out Of A Soap Opera: Biotech Exec Arrested After 21 Years On The Run
One of Rhode Island's most-wanted fugitives was captured Monday after apparently hiding out for 20 years as a biotech executive. Continue Reading
IMMX INVESTOR ALERT: Holzer & Holzer, LLC Announces Investigation of Immix Biopharma, Inc.
ATLANTA, July 20, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Immix Biopharma, Inc. (“Immix” or the “Company”) (NASDAQ: IMMX) complied with federal securities laws...
Get Immix Biopharma Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.